Technologies Product Candidates Targa Services About Us

Targa's Mission
Develop and out-license anti-cancer targeted therapeutics and drug components based on Targa Therapeutic Payload technologies.

Key Technologies: Targa Therapeutic Payloads
Highly potent cancer-killing compounds that can be readily linked or fused to antibodies or other molecules for selective targeting to tumors. These compounds represent a major advance in the field because they have shown very little toxicity to normal tissues in the body.

Targa Therapeutics Corporation is a biotechnology company based in San Diego, California and Houston, Texas. Targa was founded in October, 2002 with the goal of commercializing Targa Therapeutic Payloads, molecules that can be conjugated or fused to antibodies or other tumor targeting molecules to improve their potency/toxicity ratio (therapeutic index). Targa Therapeutic Payloads were developed by Michael G. Rosenblum, Ph.D., Head of the Section of Immunopharmacology and Targeted Therapy at The University of Texas M. D. Anderson Cancer Center in Houston, TX, one of the world’s leading cancer centers. Targa Therapeutic Payloads represent a major breakthrough in pharmaceutical technology. They can be either chemically conjugated or genetically fused to a wide variety of cell-targeting monoclonal or polyclonal antibodies, growth factors or other molecules that bind to or selectively accumulate in tumors or diseased tissue. In combination with such targeting moieties, Targa Therapeutic Payloads have the potential to improve treatment for patients with a wide variety of cancers and other hyperproliferative disorders.

Download pdf version of the Targa Therapeutics site information

Copyright © Targa Therapeutics Corp. 2003-2004 All Rights Reserved.